Scott Tagawa, MD, MS, FACP, Weill Cornell Medicine, New York, NY, USA, discusses a Phase I dose-escalation study (NCT03276572) of the PSMA-targeted alpha emitter 225Ac-J591 in men with metastatic castration-resistant prostate cancer (mCRPC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
